Fundraising FoxMission Biocapital — 2024 Investments
5 investments dated 2024 · listed companies and verified rows first · show all
Progentos develops small-molecule therapeutics to stimulate myelin regeneration in multiple sclerosis patients by activating oligodendrocyte progenitor cells.
BiotechDeep TechMedical DevicesWatertown, US
Dmitrij Hristodorov(Director)inChristopher Loose(Executive Officer, Director)Sanjay Magavi(Executive Officer)Marc-Olivier Turgeon(Director)in
BoardAleks Radovic-Moreno(Director)inDan Janney(Director)
Board seatCassidy Blundell· per SEC Form D
Co-investorsAlta PartnersDolby Family VenturesLongwood FundService Provider CapitalForbion
Alessa develops SaaS compliance software that combines KYC, KYB, AML, and fraud prevention tools for financial institutions and corporates globally.
CybersecurityEnterprise SoftwareFintechSaaSJamaica, JM
Holly Sais Phillippi(Chief Executive Officer)in
Co-investorsMassMutual VenturesJohnson & Johnson Innovation – JJDCSalesforce VenturesWavecrest Growth Partners
Babylon is a digital health company that develops prescription medications and treatments for specific health conditions.
Digital HealthHealthtechMedical Devices
BoardMichelle Arkin(PhD)
Co-investorsBackwards CapitalK5 GlobalLaunch HouseLong Journey VenturesLux CapitalMetaplanet+5 more
Nocion Therapeutics develops small molecule charged sodium channel blockers (nocions) designed to silence overactive sensory nerves.
BiotechHealthtechMedical DevicesWatertown, US
MATTHEW FRANKEL(Executive Officer)inPETER COUROSSI(Executive Officer)RICHARD BATYCKY(President and Chief Executive Officer)JAMES ELLIS(Executive Officer)MICHAEL LIPP(Executive Officer)inCHRISTOPHER SILBER(Executive Officer)in
Co-investorsCanaan PartnersF-Prime CapitalLumira VenturesMonograph Capital PartnersOUP (Osage University Partners)
Nuvig Therapeutics is a biotech company developing immune-modulating therapies for autoimmune and chronic inflammatory diseases, using an endogenous regulatory mechanism intended to treat inflammation without compromising broader immune function.
BiotechLongevity
Co-investorsSanofi VenturesAlexandriaB CapitalDigitalis VenturesGlobal BioAccess FundLeaps by Bayer+3 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.